HomeFilePharmacology

Pharmacology

View Category

Other

ESC 2018 | CLARIFY: No Survival Benefit with Beta-Blockers Beyond 1 Year After Infarction

This is another study that concludes that beta-blockers have no impact on mortality at 1 year after infarction...
solaci -
Learn More
Antiplatelet

ESC 2018 | ASCEND: Aspirin for Primary Prevention in Diabetic Patients Fails the Cost-Benefit Analysis

The obvious risk of bleeding posed by aspirin was too clear in this work, casting a shadow...
solaci -
Learn More
Acute coronary syndromes

ESC 2018 | MATRIX: 1-Year Superiority of Transradial Access

Transradial access should be the access of choice in patients with acute coronary syndrome, while bivalirudin has...
solaci -
Learn More
Antithrombotic Anticoagulants

ESC 2018 | MARINER: Rivaroxaban as Thromboprophylaxis after Hospitalization

For acute patients hospitalized for a clinical disease (e.g.: heart failure), indicating rivaroxaban for 6.5 weeks after...
solaci -
Learn More
Coronary disease

SOLACI-SOCIME 2018 | New Indications

Read articles on the main presentations of the first day of SOLACI-SOCIME 2018 Congress. See the presentation by Dr....
solaci -
Learn More
Coronary disease

Women in Cardiology: Still Underrepresented in a Field Full of Men

JAMA Cardiology dedicated a special with 4 articles on different issues women continue to face when considering...
solaci -
Learn More
Other

New European Hypertension Guidelines Contrast with American Recommendations

The European guidelines on hypertension have been updated and now feature differences compared with American guidelines regarding...
solaci -
Learn More
Antiplatelet

Can We Prevent Cardiovascular Events without Aspirin?

As regards the use of antithrombotic agents, the risk of bleeding will always be an issue, and...
solaci -
Learn More